Press Releases

Patients In Trial Continuing To Be Treated Per Protocol, Including In Germany   BETHESDA, MD, August 21, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax®-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to... Read More

86% of Phase I patients treated with preferred method still alive   Bethesda, MD, June 1, 2015– Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors. The patients enrolled in the... Read More

Will Include Survival Data To Date and Other Findings BETHESDA, MD, May 27, 2015 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix L. Bosch, Chief Technical Officer of the Company, will be making an Industry Expert Theater Presentation at the 2015 ASCO Annual Meeting in Chicago on Saturday, May 30, 2015, from 3... Read More

BETHESDA, MD, May 21, 2015 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix L. Bosch, Chief Technical Officer of the Company, will be making a presentation at the New York Academy of Sciences’ Conference on Emerging Approaches to Immunotherapy at 11:40 a.m. on May 21, 2015, at the Academy in New York... Read More

Company invites individual and institutional investors as well as advisors to attend real-time VirtualInvestorConferences.com BETHESDA, MD, May 6, 2015– Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Linda Powers, NW Bio CEO, will present a live overview of the Company’s DCVax cancer vaccine platform for... Read More